Ocugen to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference
27 Setembro 2023 - 8:30PM
Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies, biologics, and
vaccines, today announced that Dr. Shankar Musunuri, Chairman,
Chief Executive Officer and Co-Founder and Dr. Huma Qamar, MPH,
CMI, Head of Clinical Development and Medical Affairs will
participate in an in-person fireside chat moderated by Daniil
Gataulin, PhD, Senior Biotech Research Analyst at the Chardan 7th
Annual Genetic Medicines Conference being held October 2-3, 2023 in
NYC.
Details regarding the fireside chat are as follows:
Date: October 2, 2023
Location: Westin Grand Central, New York,
NY
Time: 1:30 p.m. ET
Webcast Link:
https://ir.ocugen.com/events/event-details/chardans-7th-annual-genetic-medicines-conference
In addition, Ocugen will conduct one-on-one meetings with
registered investors to showcase the Company’s business and
clinical development strategy across its unique gene therapy, cell
therapy, and vaccine platforms, and highlight recent corporate
achievements, including the Company’s recent positive Phase 1/2
OCU400 clinical study update and anticipated milestones.
A live video webcast of the fireside chat will be available on
the events page of the Ocugen investor site.
About Ocugen, Inc. Ocugen, Inc. is a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies, biologics, and
vaccines that improve health and offer hope for patients across the
globe. We are making an impact on patients’ lives through
courageous innovation—forging new scientific paths that harness our
unique intellectual and human capital. Our breakthrough modifier
gene therapy platform has the potential to treat multiple retinal
diseases with a single product, and we are advancing research in
infectious diseases to support public health and orthopedic
diseases to address unmet medical needs. Discover more
at www.ocugen.com and follow us
on Twitter and LinkedIn.
Forward-Looking Statements This press
release contains forward-looking statements within the meaning of
The Private Securities Litigation Reform Act of 1995, which are
subject to risks and uncertainties. We may, in some cases, use
terms such as “predicts,” “believes,” “potential,” “proposed,”
“continue,” “estimates,” “anticipates,” “expects,” “plans,”
“intends,” “may,” “could,” “might,” “will,” “should,” or other
words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. Such statements are
subject to numerous important factors, risks, and uncertainties
that may cause actual events or results to differ materially from
our current expectations. These and other risks and uncertainties
are more fully described in our periodic filings with the
Securities and Exchange Commission (SEC), including the risk
factors described in the section entitled “Risk Factors” in the
quarterly and annual reports that we file with the SEC. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. Except as required by
law, we assume no obligation to update forward-looking statements
contained in this press release whether as a result of new
information, future events, or otherwise, after the date of this
press release.
Contact: Tiffany Hamilton Head of
Communications Tiffany.Hamilton@ocugen.com
Ocugen (NASDAQ:OCGN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Ocugen (NASDAQ:OCGN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024